The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index.
Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid
Abstract
The preclinical pharmacology of the alpha4beta2 nicotinic acetylcholine receptor (nAChR) partial agonist varenicline, a novel smoking cessation agent is described. Varenicline binds with subnanomolar affinity only to alpha4beta2 nAChRs and in vitro functional patch clamp studies in HEK cells expressing nAChRs show that varenicline is a partial agonist with 45% of nicotine's maximal efficacy at alpha4beta2 nAChRs. In neurochemical models varenicline has significantly lower (40-60%) efficacy than nicotine in stimulating [(3)H]-dopamine release from rat brain slices in vitro and in increasing dopamine release from rat nucleus accumbens in vivo, while it is more potent than nicotine. In addition, when combined with nicotine, varenicline effectively attenuates the nicotine-induced dopamine release to the level of the effect of varenicline alone, consistent with partial agonism. Finally, varenicline reduces nicotine self-administration in rats and supports lower self-administration break points than nicotine. These data suggest that varenicline can reproduce to some extent the subjective effects of smoking by partially activating alpha4beta2 nAChRs, while preventing full activation of these receptors by nicotine. Based on these findings, varenicline was advanced into clinical development and recently shown to be an effective and safe aid for smoking cessation treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“neither patch (Jorenby et al., 1995) nor varenicline are reinforcing (Rollema et al., 2007).”
From It is not “either/or”: Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood (2008) · cites this paper as Rollema et al., 2007
In the citing paper
“Varenicline, the most effective medication for smoking cessation currently available (Chantix; Pfizer), is a potent partial agonist for a4b2 nAChRs, as well as a weak partial agonist at a3b4 nAChRs and a full agonist at a7 nAChRs (Coe et al, 2005; Rollema et al, 2007).”
From Divergent Functional Effects of Sazetidine-A and Varenicline During Nicotine Withdrawal (2013) · cites this paper as Rollema et al, 2007
In the citing paper
“Varenicline, the most effective medication for smoking cessation currently available (Chantix; Pfizer), is a potent partial agonist for a4b2 nAChRs, as well as a weak partial agonist at a3b4 nAChRs and a full agonist at a7 nAChRs (Coe et al, 2005; Rollema et al, 2007).”
From Divergent Functional Effects of Sazetidine-A and Varenicline During Nicotine Withdrawal (2013) · cites this paper as Rollema et al, 2007
In the citing paper
“Varenicline, the most effective medication for smoking cessation currently available (Chantix; Pfizer), is a potent partial agonist for a4b2 nAChRs, as well as a weak partial agonist at a3b4 nAChRs and a full agonist at a7 nAChRs (Coe et al, 2005; Rollema et al, 2007).”
From Divergent Functional Effects of Sazetidine-A and Varenicline During Nicotine Withdrawal (2013) · cites this paper as Rollema et al, 2007
In the citing paper
“Varenicline (Chantix; Pfizer, Groton, CT) is a potent partial agonist at ␣42 nAChRs, with 40 to 60% of the agonist efficacy of nicotine (Rollema et al., 2007), and it is a less potent partial agonist at ␣34 and a full agonist at ␣7 nAChRs (Mihalak et al., 2006;Rollema et al., 2007Rollema et al., , 2009b)).”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Rollema et al., 2007
In the citing paper
“Varenicline (Chantix; Pfizer, Groton, CT) is a potent partial agonist at ␣42 nAChRs, with 40 to 60% of the agonist efficacy of nicotine (Rollema et al., 2007), and it is a less potent partial agonist at ␣34 and a full agonist at ␣7 nAChRs (Mihalak et al., 2006;Rollema et al., 2007Rollema et al., , 2009b)).”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Rollema et al., 2007
In the citing paper
“Although the K i values for sazetidine-A and varenicline at ␣42 nAChRs are very similar (0.4 and 0.2 nM, respectively) (Xiao et al., 2006;Rollema et al., 2007)”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Rollema et al., 2007
In the citing paper
“the high-affinity ␣42 partial agonist varenicline also has moderate affinity for other nAChRs and acts as a partial agonist at ␣34 and a full agonist at ␣7 nAChRs (Mihalak et al., 2006;Rollema et al., 2007).”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Rollema et al., 2007
In the citing paper
“Although varenicline, like cytisine, is a potent and selective ␣42 partial agonist (Rollema et al., 2007)”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Rollema et al., 2007
In the citing paper
“Varenicline has at least 100-fold higher affinity for α4β2 than for other subtypes, is a 45% agonist as compared with nicotine and can potently desensitize α4β2 nicotinic acetylcholine receptors with an IC50 value of 6 nM for inhibiting nicotine-evoked currents (Rollema et al., 2007).”
From Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect (2009) · cites this paper as Rollema et al., 2007
In the citing paper
“The fact that low doses of varenicline (i.e. 0.25 mg/kg in C57BL/6J mice and 0.178 mg/kg in CD-1 mice) have significant effects in both experiments is consistent with varenicline’s high in vitro binding affinity (Ki = 0.15 nM) and inactivating potency (IC50 = 6 nM) at α4β2 nicotinic acetylcholine receptors, as well as with its potent activity in in vivo models, such as increasing mesolimbic”
From Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect (2009) · cites this paper as Rollema et al., 2007
In the citing paper
“Varenicline has at least 100-fold higher affinity for α4β2 than for other subtypes, is a 45% agonist as compared with nicotine and can potently desensitize α4β2 nicotinic acetylcholine receptors with an IC50 value of 6 nM for inhibiting nicotine-evoked currents (Rollema et al., 2007).”
From Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect (2009) · cites this paper as Rollema et al., 2007
In the citing paper
“Varenicline has at least 100-fold higher affinity for α4β2 than for other subtypes, is a 45% agonist as compared with nicotine and can potently desensitize α4β2 nicotinic acetylcholine receptors with an IC50 value of 6 nM for inhibiting nicotine-evoked currents (Rollema et al., 2007).”
From Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect (2009) · cites this paper as Rollema et al., 2007
Citations
Cites
Mortality in relation to smoking: 40 years' observations on male British doctors
Doll, R., Peto, R., Wheatley, K., Gray, R., & Sutherland, I. (1994) · BMJ · doi:10.1136/bmj.309.6959.901 · Cited by 5,932
Neural systems of reinforcement for drug addiction: from actions to habits to compulsion
Everitt, B. J., & Robbins, T. W. (2005) · Nature Neuroscience · doi:10.1038/nn1579 · Cited by 3,785
Mortality in relation to smoking: 50 years' observations on male British doctors
Doll, R., Peto, R., Boreham, J., & Sutherland, I. (2004) · BMJ · doi:10.1136/bmj.38142.554479.ae · Cited by 2,920 · cited 1×
“Department of Health and Human Services, 2004; Doll et al., 2004 ).”
BackgroundThe Health Consequences of Smoking: A Report of the Surgeon General
Office on Smoking (2004) · Cited by 2,414
Charbonneau, D. H. (2005) · Europe PMC (PubMed Central) · Cited by 2,041
Picciotto, M. R., Zoli, M., Rimondini, R., Léna, C., Marubio, L. M., Pich, E. M., Fuxe, K., & Changeux, J.-P. (1998) · Nature · doi:10.1038/34413 · Cited by 1,320
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Self-citation
Flagged first, then by citations
2 of the 44 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 554
The impact of pre-cessation varenicline on behavioral economic indices of smoking reinforcement
Schlienz, N. J., Hawk, L. W., Tiffany, S. T., O’Connor, R. J., & Mahoney, M. C. (2014) · Addictive Behaviors · doi:10.1016/j.addbeh.2014.05.008 · Cited by 29
Henderson, B. J., Carper, D. J., González-Cestari, T. F., Yi, B., Mahasenan, K. V., Pavlovicz, R. E., Dalefield, M. L., Coleman, R. S., Li, C., & McKay, D. B. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201294r · Cited by 30
Sofuoglu, M., Herman, A. I., Li, Y., & Waters, A. J. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2763-4 · Cited by 29
Kimmey, B. A., Rupprecht, L. E., Hayes, M. R., & Schmidt, H. D. (2012) · Addiction Biology · doi:10.1111/adb.12014 · Cited by 29
Smoking cessation therapy with varenicline
Krishna, G. (2008) · International Journal of COPD · doi:10.2147/copd.s1848 · Cited by 28
de Moura, F. B., & McMahon, L. R. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4514-4 · Cited by 29
Nirogi, R. V. S., Mohammed, A. R., Shinde, A. K., Ravella, S. R., Bogaraju, N., Subramanian, R., Mekala, V. R., Palacharla, V. R. C., Muddana, N., Thentu, J. B., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00790 · Cited by 28
Patterns of nicotinic receptor antagonism II: Cardiovascular effects in rats
Jutkiewicz, E. M., Rice, K. C., Carroll, F. I., & Woods, J. H. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.021 · Cited by 28
Smoking cessation: present status and future perspectives
Caponnetto, P., Russo, C., & Polosa, R. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.02.005 · Cited by 30
Levamisole enhances the rewarding and locomotor-activating effects of cocaine in rats
Tallarida, C. S., Tallarida, R. J., & Rawls, S. M. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.01.035 · Cited by 28
Kruk-Słomka, M., Budzyńska, B., & Biała, G. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70904-0 · Cited by 29
The effects of varenicline on stress-induced and cue-induced craving for cigarettes
Ray, L. A., Lunny, K., Bujarski, S., Moallem, N., Krull, J. L., & Miotto, K. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.015 · Cited by 27
Paterson, N. E. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32832c7083 · Cited by 27
Association of nAChR gene haplotypes with heavy alcohol use and body mass
Landgren, S., Engel, J. A., Andersson, M. E., González‐Quintela, A., Franco, J. C., Nilsson, S., Zetterberg, H., Blennow, K., & Jerlhag, E. (2009) · Brain Research · doi:10.1016/j.brainres.2009.08.026 · Cited by 27
Effectiveness of varenicline for smoking cessation: A 1-year follow-up study
Grassi, M., Enea, D., Ferketich, A. K., Lü, B., Pasquariello, S., & Nencini, P. (2011) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2011.01.014 · Cited by 27
Orthosteric and Allosteric Ligands of Nicotinic Acetylcholine Receptors for Smoking Cessation
Mohamed, T. S., Jayakar, S. S., & Hamouda, A. K. (2015) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2015.00071 · Cited by 27
Bolchi, C., Gotti, C., Binda, M., Fumagalli, L., Pucci, L., Pistillo, F., Vistoli, G., Valoti, E., & Pallavicini, M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200937t · Cited by 27
Kozikowski, A. P., Chellappan, S. K., Xiao, Y., Bajjuri, K. M., Yuan, H., Kellar, K. J., & Petukhov, P. A. (2007) · ChemMedChem · doi:10.1002/cmdc.200700073 · Cited by 28
Mello, N. K., Fivel, P. A., Kohut, S. J., & Carroll, F. I. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.325 · Cited by 26
Pharmacologic Characterization of a Nicotine-Discriminative Stimulus in Rhesus Monkeys
Cunningham, C. S., Javors, M. A., & McMahon, L. R. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.193078 · Cited by 26
Lange‐Asschenfeldt, C., Schäble, S., Suvorava, T., Gholamreza-Fahimi, E., Bisha, M., Stermann, T., Henning, U., & Kojda, G. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.025 · Cited by 26
The role of nicotinic acetylcholine receptors in alcohol-related behaviors
Miller, C. N., & Kamens, H. M. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.07.017 · Cited by 28
Lotfipour, S., Mandelkern, M. A., Alvarez-Estrada, M., & Brody, A. L. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.20 · Cited by 26
Arias, H. R., Feuerbach, D., Targowska‐Duda, K. M., Kaczor, A. A., Poso, A., & Jóźwiak, K. (2014) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2014.11.003 · Cited by 25
Mecamylamine treatment for alcohol dependence: a randomized controlled trial
Petrakis, I. L., Ralevski, E., Gueorguieva, R. V., O’Malley, S. S., Arias, A. J., Sevarino, K. A., Jane, J. S., O’Brien, E. M., & Krystal, J. H. (2017) · Addiction · doi:10.1111/add.13943 · Cited by 25
Optimization of a nicotine degrading enzyme for potential use in treatment of nicotine addiction
Thisted, T., Biesová, Z., Walmacq, C., Stone, E. M., Rodnick-Smith, M., Ahmed, S. S., Horrigan, S. K., van Engelen, B., Reed, C., & Kalnik, M. W. (2019) · BMC Biotechnology · doi:10.1186/s12896-019-0551-5 · Cited by 25
Flannery, J. S., Riedel, M. C., Poudel, R., Laird, A. R., Ross, T. J., Salmeron, B. J., Stein, E. A., & Sutherland, M. T. (2019) · Science Advances · doi:10.1126/sciadv.aax2084 · Cited by 26
Negus, S. S., & Banks, M. L. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173264 · Cited by 24
Partial Agonism of 5-HT3Receptors: A Novel Approach to the Symptomatic Treatment of IBS-D
Moore, N. A., Sargent, B. J., Manning, D. D., & Guzzo, P. R. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300166c · Cited by 24
Tobacco addiction: A biochemical model of nicotine dependence
Ortells, M. O., & Barrantes, G. E. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2009.11.004 · Cited by 26
Ravva, P., Gastonguay, M. R., French, J. L., Tensfeldt, T. G., & Faessel, H. M. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.282 · Cited by 24
Cunningham, C. S., & McMahon, L. R. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.12.003 · Cited by 24
Gubner, N. R., McKinnon, C. S., & Phillips, T. J. (2014) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12588 · Cited by 23
Tobey, K. M., Walentiny, D. M., Wiley, J. L., Carroll, F. I., Damaj, M. I., Azar, M. R., Koob, G. F., George, O., Harris, L. S., & Vann, R. E. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2703-3 · Cited by 23
Perkins, K. A., Mercincavage, M., Fonte, C. A., & Lerman, C. E. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1816-9 · Cited by 23
Biała, G., & Staniak, N. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.04.022 · Cited by 23
Effect of varenicline on aspects of inhibitory control in smokers
Austin, A. J., Duka, T., Rusted, J. M., & Jackson, A. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3512-7 · Cited by 23
Söderpalm, B., Danielsson, K., de Bejczy, A., Adermark, L., & Ericson, M. (2019) · Addiction Biology · doi:10.1111/adb.12807 · Cited by 23
Xi, Z. (2010) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s6299 · Cited by 26
Dose-dependent and sustained effects of varenicline on dopamine D2/3 receptor availability in rats
Crunelle, C. L., Schulz, S., de Bruin, K. M., Miller, M. L., van den Brink, W., & Booij, J. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.11.001 · Cited by 23
Ortiz, N. C., O'Neill, H. C., Marks, M. J., & Grady, S. R. (2012) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntr284 · Cited by 22
VUF10166, a Novel Compound with Differing Activities at 5-HT3A and 5-HT3AB Receptors
Thompson, A. J., Verheij, M. H. P., de Esch, I. J. P., & Lummis, S. C. R. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.190769 · Cited by 22
McCaul, M. E., Wand, G. S., Kuwabara, H., Dannals, R. F., Wong, D. F., & Xu, X. (2019) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntz080 · Cited by 24
Ren, J. T., Ding, X., & Greer, J. J. (2020) · Anesthesiology · doi:10.1097/aln.0000000000003128 · Cited by 22
Swalve, N. L., Smethells, J. R., & Carroll, M. E. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.04.023 · Cited by 23
Waeiss, R. A., Knight, C. P., Hauser, S. R., Pratt, L. A., McBride, W. J., & Rodd, Z. A. (2019) · Psychopharmacology · doi:10.1007/s00213-019-5174-y · Cited by 22
Coe, J. W., Rollema, H., & O’Neill, B. T. (2009) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(09)04404-2 · Cited by 22
Self-citationRamon, J. M., & Bruguera, E. (2009) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph6041530 · Cited by 22
Multiple binding sites in the nicotinic acetylcholine receptors: An opportunity for polypharmacolgy
Iturriaga‐Vásquez, P., Alzate‐Morales, J. H., Bermúdez, I., Varas, R., & Reyes-Parada, M. I. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.08.018 · Cited by 22
Cardiovascular effects of pharmacologic therapies for smoking cessation
Sobieraj, D. M., White, W. B., & Baker, W. L. (2012) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2012.11.003 · Cited by 21
Varenicline for smoking cessation
Tonstad, S. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.2.121 · Cited by 21
Politis, A., Ioannidis, V., Gourgoulianis, K. I., Daniil, Z. D., & Hatzoglou, C. (2017) · Chronic Respiratory Disease · doi:10.1177/1479972317740128 · Cited by 21
Bold, K. W., Zweben, A., Fucito, L. M., Piepmeier, M. E., Muvvala, S. B., Wu, R., Gueorguieva, R. V., & O’Malley, S. S. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13994 · Cited by 21
Hansen, C. P., Jensen, A. A., Christensen, J. K., Balle, T., Liljefors, T., & Frølund, B. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701625v · Cited by 21
Review: Nicotinic receptors and stages of nicotine dependence
Brennan, K., Lea, R. A., Fitzmaurice, P. S., & Truman, P. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108100256 · Cited by 22
Kazan, T., & Charntikov, S. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.12.031 · Cited by 20
Coen, K. M., Adamson, K. L., & Corrigall, W. A. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1321-6 · Cited by 20
Varenicline and cardiovascular adverse events: a perspective review
Chelladurai, Y., & Singh, S. (2014) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098614530421 · Cited by 19
Tetrapeptide Ac-HAEE-NH2 Protects α4β2 nAChR from Inhibition by Aβ
Barykin, E. P., Garifulina, A. I., Tolstova, A. P., Anashkina, A. A., Adzhubei, A. A., Mezentsev, Y. V., Shelukhina, I. V., Kozin, S. A., Tsetlin, V. I., & Makarov, A. А. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176272 · Cited by 20
Weber, M. L., Hofland, C. M., Shaffer, C. L., Flik, G., Cremers, T. I. F. H., Hurst, R. S., & Rollema, H. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.027 · Cited by 19
Self-citationCiudad‐Roberts, A., Camarasa, J., Pubill, D., & Escubedo, E. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.02.013 · Cited by 19
Cunningham, C. S., & McMahon, L. R. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3037-5 · Cited by 19
DuBois, D. W., Damborsky, J. C., Fincher, A. S., Frye, G. D., & Winzer‐Serhan, U. H. (2013) · Life Sciences · doi:10.1016/j.lfs.2012.12.013 · Cited by 19
Wheelock, M. D., Reid, M. A., To, H., White, D. M., Cropsey, K. L., & Lahti, A. C. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00158 · Cited by 19
Varenicline for tobacco dependence: panacea or plight?
Williams, J. M., Steinberg, M. B., Steinberg, M. L., Gandhi, K. K., Ulpe, R., & Foulds, J. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.587121 · Cited by 19
van de Nobelen, S., Kienhuis, A. S., & Talhout, R. (2016) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntw002 · Cited by 19
Yuan, M., Malagon, A. M., Yasuda, D. M., Belluzzi, J. D., Leslie, F. M., & Zaveri, N. T. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.07.004 · Cited by 20
Phillips, A. G., Geyer, M. A., & Robbins, T. W. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.01.014 · Cited by 21
Potasiewicz, A., Gołębiowska, J., Popik, P., & Nikiforuk, A. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118812097 · Cited by 19
Loftén, A., Adermark, L., Ericson, M., & Söderpalm, B. (2020) · Addiction Biology · doi:10.1111/adb.12959 · Cited by 19
Delgado‐Vélez, M., Quesada, O., Villalobos‐Santos, J. C., Maldonado‐Hernández, R., Asmar-Rovira, G. A., Stevens, R. C., & Lasalde‐Dominicci, J. A. (2021) · Molecules · doi:10.3390/molecules26195753 · Cited by 19
Varenicline modulates ethanol and saccharin consumption in adolescent male and female C57BL/6J mice
Kamens, H. M., Silva, C. P., Peck, C., & Miller, C. N. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.07.020 · Cited by 19
Faessel, H. M., Burstein, A. H., Troutman, M. D., Willavize, S. A., Rohrbacher, K. D., & Clark, D. J. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0530-6 · Cited by 19
Phusahat, P., Dilokthornsakul, P., Boonsawat, W., Zaeoue, U., Hansuri, N., Tawinkan, N., Theeranut, A., & Lertsinudom, S. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192013358 · Cited by 18
Crunelle, C. L., de Wit, T. C., de Bruin, K. M., Ramakers, R. M., van der Have, F., Beekman, F. J., van den Brink, W., & Booij, J. (2012) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2011.11.006 · Cited by 18
Differentiating the primary reinforcing and reinforcement-enhancing effects of varenicline
Schassburger, R. L., Levin, M. E., Weaver, M. T., Palmatier, M. I., Caggiula, A. R., Donny, E. C., & Sved, A. F. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3732-x · Cited by 19
Scuppa, G., Cippitelli, A., Toll, L., Ciccocioppo, R., & Ubaldi, M. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.09.002 · Cited by 19
A comparison of brain and behavioral effects of varenicline and nicotine in rats
King, J. A., Huang, W., Chen, W., Heffernan, M. E., Shields, J. A., Rane, P., Bircher, R., & DiFranza, J. R. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.04.012 · Cited by 18
Kadi, A. A., Mohamed, M. S., Kassem, M. G., & Darwısh, I. A. (2011) · Chemistry Central Journal · doi:10.1186/1752-153x-5-30 · Cited by 18
Varenicline in smoking cessation
Tonstad, S., & Rollema, H. (2010) · Expert Review of Respiratory Medicine · doi:10.1586/ers.10.27 · Cited by 18
Self-citationKaduri, P., Voci, S. C., Zawertailo, L. A., Chaiton, M., McKenzie, K. J., & Selby, P. L. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000111 · Cited by 18
Bidwell, L. C., Karoly, H. C., Hutchison, K. E., & Bryan, A. D. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.06.020 · Cited by 18
Sub-anesthetic doses of ketamine attenuate nicotine self-administration in rats
Rezvani, A. H., Tizabi, Y., Slade, S. K., Getachew, B., & Levin, E. D. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.01.022 · Cited by 18
Rollema, H., Wilson, G. G., Lee, T. C., Folgering, J. H. A., & Flik, G. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.10.015 · Cited by 17
Self-citationKumar, M., Keady, J. V., Aryal, S. P., Hessing, M. C., Richards, C. I., & Turner, J. R. (2023) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2023.08.019 · Cited by 17
Crestini, A., Carbone, E., Rivabene, R., Ancidoni, A., Rosa, P., Tata, A. M., Fabrizi, E., Locuratolo, N., Vanacore, N., Lacorte, E., et al. (2024) · Cells · doi:10.3390/cells13030237 · Cited by 20
Varenicline effects on cocaine self administration and reinstatement behavior
Guillem, K., & Peoples, L. L. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e328336e9c5 · Cited by 17
Nicotine Addiction: Mechanisms and Consequences
Rosenthal, D. G., Weitzman, M. L., & Benowitz, N. L. (2011) · International Journal of Mental Health · doi:10.2753/imh0020-7411400102 · Cited by 18
Pharmacotherapies and harm-reduction options for the treatment of tobacco dependence
Houezec, J. L., & Aubin, H. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.818978 · Cited by 17
Bolchi, C., Bavo, F., Gotti, C., Fumagalli, L., Fasoli, F., Binda, M., Mucchietto, V., Sciaccaluga, M., Plutino, S., Fucile, S., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.10.048 · Cited by 17
Laikowski, M. M., Reisdorfer, F., & Moura, S. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180410105135 · Cited by 17
Mild‐to‐severe poisoning due to Conium maculatum as toxic herb: A case series
Boskabadi, S. J., Askari, Z., Zakariaei, Z., Fakhar, M., & Tabaripour, R. (2021) · Clinical Case Reports · doi:10.1002/ccr3.4509 · Cited by 17
Wadsworth, H. A., Anderson, E. Q., Williams, B. M., Ronström, J. W., Moen, J. K., Lee, A. M., McIntosh, J. M., Wu, J., Yorgason, J. T., & Steffensen, S. C. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03263-5 · Cited by 17
Design, Synthesis and Discovery of Picomolar Selective α4β2 Nicotinic Acetylcholine Receptor Ligands
Yenugonda, V. M., Xiao, Y., Levin, E. D., Rezvani, A. H., Tran, T. P., Al‐Muhtasib, N., Sahibzada, N., Xie, T., Wells, C., Slade, S. K., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4008455 · Cited by 17
Agonist and antagonist effects of cytisine in vivo
Radchenko, E. V., Драволина, О. А., & Bespalov, A. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.03.019 · Cited by 19
Pittenger, S. T., Barrett, S. T., Chou, S., & Bevins, R. A. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.11.033 · Cited by 16
Sansores, R. H., Ramírez‐Venegas, A., Arellano-Rocha, R., Noé-Díaz, V., García‐Gómez, L., Pérez-Bautista, O., & Velázquez-Uncal, M. (2016) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816654823 · Cited by 16
Henningfield, J. E., Smith, T. T., Kleykamp, B. A., Fant, R. V., & Donny, E. C. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4441-4 · Cited by 17
Self-Administration of Cotinine in Wistar Rats: Comparisons to Nicotine
Ding, Z., Gao, Y., Sentir, A. M., & Tan, X. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000367 · Cited by 16
Preventing Lung Cancer by Treating Tobacco Dependence
Hurt, R. D., Ebbert, J. O., Hays, J. T., & McFadden, D. D. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.08.004 · Cited by 16
Metadata
- Authors
- Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., Sands, S. B., Schaeffer, E., Schulz, D. W., Tingley, F. D., & Williams, K. E.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Rollema, H.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2007-03
- Volume
- 52
- Issue
- 3
- Pages
- 985-994
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2101520329
- Cited by
- 533
- References
- 44
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 9 · 2023: 13 · 2022: 16 · 2021: 19 · 2020: 27 · 2019: 25 · 2018: 27 · 2017: 20 · 2016: 27 · 2015: 37 · 2014: 34 · 2013: 34 · 2012: 41
- FWCI
- 13.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuropharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- varenicline, α4β2 nicotinic acetylcholine receptor, partial agonism, smoking cessation, nicotine self-administration, dopamine release, nucleus accumbens, receptor binding affinity
- MeSH terms
- Varenicline, Animals, Behavior, Animal, Benzazepines, Brain, Cell Line, Transformed, Dopamine, Dose-Response Relationship, Drug, Drug Administration Schedule, Humans, Male, Membrane Potentials, Nicotine, Protein Binding, Quinoxalines, Self Administration, Transfection, Smoking Cessation, Rats, Sprague-Dawley, Patch-Clamp Techniques, Nicotinic Agonists, Rats, Long-Evans, Rats, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
